Khurana, N.; Chandra, P.K.; Kim, H.; Abdel-Mageed, A.B.; Mondal, D.; Sikka, S.C.
Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells. Antioxidants 2020, 9, 68.
https://doi.org/10.3390/antiox9010068
AMA Style
Khurana N, Chandra PK, Kim H, Abdel-Mageed AB, Mondal D, Sikka SC.
Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells. Antioxidants. 2020; 9(1):68.
https://doi.org/10.3390/antiox9010068
Chicago/Turabian Style
Khurana, Namrata, Partha K. Chandra, Hogyoung Kim, Asim B. Abdel-Mageed, Debasis Mondal, and Suresh C. Sikka.
2020. "Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells" Antioxidants 9, no. 1: 68.
https://doi.org/10.3390/antiox9010068
APA Style
Khurana, N., Chandra, P. K., Kim, H., Abdel-Mageed, A. B., Mondal, D., & Sikka, S. C.
(2020). Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells. Antioxidants, 9(1), 68.
https://doi.org/10.3390/antiox9010068